Indaptus raises $6M via convertible preferred; Lazar appointed Chairman and Co-CEO

Indaptus Therapeutics, Inc.

David Lazar invests $6M for 300K Series AA and 700K Series AAA shares convertible into 111M common shares after stockholder approval.
Lazar appointed Chairman and Co-CEO; board adds Avraham Ben-Tzvi; directors Martell and Karah resign.
Special meeting by Mar 31, 2026 to approve conversion, authorized share increase, written consent, reverse split, and Lazar board nominees.
Executive officers modify employment: reduce notice to 10 days, waive severance for stock/cash; CMO Waltzman resigns with $207K bonus.
Issuance under Regulation S exemption; proceeds for operations, severance, working capital.

item 1.01 item 3.02 item 3.03 item 5.03 item 5.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.